A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
Public ClinicalTrials.gov record NCT07363720. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of this study is to assess how effective TAK-861 is for treating narcolepsy type 1 and if this effect is maintained over time. Participants will take TAK-861 for a few months and if they meet certain criteria, they will be randomly assigned (by chance, like flipping a coin) to continue taking TAK-861 or take placebo (fake medicine) for up to 4 weeks to see if their narcolepsy symptoms return.
Study identification
- NCT ID
- NCT07363720
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 98 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 29, 2026 (Actual)
- Primary completion
- Oct 2, 2026 (Estimated)
- Completion
- Oct 2, 2026 (Estimated)
- Last update posted
- Sep 1, 2026
2026
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Takeda Site 15 | Redwood City | California | 94063 | — |
| Takeda Site 19 | Brandon | Florida | 33511 | — |
| Takeda Site 22 | Miami | Florida | 33155 | — |
| Takeda Site 23 | Southfield | Michigan | 48075 | — |
| Takeda Site 20 | Middletown | New Jersey | 07748 | — |
| Takeda Site 24 | Durham | North Carolina | 27710-4000 | — |
| Takeda Site 25 | Winston-Salem | North Carolina | 27103 | — |
| Takeda Site 16 | Cincinnati | Ohio | 45245 | — |
| Takeda Site 18 | Cleveland | Ohio | 44195 | — |
| Takeda Site 17 | Columbia | South Carolina | 29201 | — |
| Takeda Site 21 | Austin | Texas | 78731 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07363720, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07363720 live on ClinicalTrials.gov.